Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support ...
The third-line results build on equally compelling second-line data, where pelareorep achieved a 30% response rate, more than doubling the 13.8% benchmark for the only FDA-approved immunotherapy in ...
First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries - Investigator-Initiated (IIT) funded pancreatic and brain cancer trials HOUSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) ...
4hon MSN
Autologous T cell therapy targeting multiple antigens shows promise in treating pancreatic cancer
A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising ...
Sensorineural hearing loss (SNHL) is a highly prevalent sensory disorder globally, affecting over 1.5 billion people, with a ...
Evidence shows electric vehicle adoption is nearing a tipping point, with declining battery costs and enhanced infrastructure ...
The nearly 30-year tale of secalosides A and B began in 1997, when natural product chemists identified them as components of rye pollen extract. Although the compounds were inactive in lab tests with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback